[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,971,440
  • Shares Outstanding, K 2,041,735
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,645 M
  • EBITDA $ 16,656 M
  • 60-Month Beta 0.27
  • Price/Sales 2.49
  • Price/Cash Flow 7.22
  • Price/Book 6.46

Options Overview Details

View History
  • Implied Volatility 31.95% (-1.27%)
  • Historical Volatility 24.65%
  • IV Percentile 67%
  • IV Rank 56.12%
  • IV High 40.88% on 11/19/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 3) 2.36 (4.07%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 16,405
  • Volume Avg (30-Day) 21,364
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 539,314
  • Open Int (30-Day) 537,412
  • Expected Range 55.65 to 60.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.44
  • Number of Estimates 10
  • High Estimate $1.53
  • Low Estimate $1.35
  • Prior Year $1.80
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.22 +1.53%
on 04/15/26
62.22 -6.64%
on 04/01/26
-0.44 (-0.76%)
since 03/27/26
3-Month
54.21 +7.17%
on 01/29/26
62.89 -7.62%
on 03/02/26
+3.48 (+6.36%)
since 01/28/26
52-Week
42.52 +36.63%
on 10/29/25
62.89 -7.62%
on 03/02/26
+9.64 (+19.88%)
since 04/28/25

Most Recent Stories

More News
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 30.64 (+5.04%)
CRSP : 52.22 (+2.41%)
MRK : 110.09 (-0.13%)
BMY : 58.22 (+0.76%)
NTLA : 13.37 (+2.53%)
Mega-Cap Earnings, FOMC and Other Key Things to Watch this Week

Markets enter a pivotal week with key Mega-Cap earnings and Fed policy the main tings to watch along with any news from Iran.

META : 671.43 (-1.06%)
GOOGL : 350.92 (+0.17%)
AAPL : 270.88 (+1.22%)
CVX : 187.99 (+1.74%)
KO : 78.17 (+3.62%)
F : 12.38 (-0.88%)
GM : 78.93 (+1.24%)
MRK : 110.09 (-0.13%)
AMGN : 339.63 (-0.16%)
BMY : 58.22 (+0.76%)
MSFT : 429.90 (+1.20%)
SBUX : 96.98 (-0.93%)
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

Expands Options for Cash-Paying Patients to Access the Nation’s #1 Prescribed Oral Blood Thinner

PFE : 26.39 (-1.49%)
BMY : 58.22 (+0.76%)
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

SAN DIEGO , April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced...

RNA : 12.54 (-2.79%)
BMY : 58.22 (+0.76%)
1 Unpopular Stock That Should Get More Attention and 2 We Question

1 Unpopular Stock That Should Get More Attention and 2 We Question

PRIM : 169.41 (-2.08%)
CAT : 817.35 (-1.38%)
BMY : 58.22 (+0.76%)
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 5.97 (-0.33%)
BMY : 58.22 (+0.76%)
Bristol-Myers Squibb Earnings Preview: What to Expect

Bristol-Myers Squibb is approaching its first-quarter earnings release this month, and Wall Street is forecasting a double-digit percentage fall in earnings.

XLV : 143.82 (+0.25%)
$SPX : 7,136.98 (-0.51%)
BMY : 58.22 (+0.76%)
Gilead to Acquire Tubulis for Up to $5 Billion to Expand Cancer Drug Pipeline

Gilead Sciences ($GILD) said Tuesday it will acquire Germany-based Tubulis GmbH for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, as the company expands...

GILD : 129.15 (+1.10%)
BMY : 58.22 (+0.76%)
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

AMN : 20.95 (-0.14%)
ABBV : 197.61 (+0.12%)
NVAX : 7.93 (-1.73%)
DVA : 150.22 (+0.11%)
BMY : 58.22 (+0.76%)
3 Value Stocks Walking a Fine Line

3 Value Stocks Walking a Fine Line

APAM : 37.95 (-0.47%)
UTZ : 8.01 (+2.69%)
BMY : 58.22 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 60.12
2nd Resistance Point 59.62
1st Resistance Point 58.70
Last Price 58.22
1st Support Level 57.28
2nd Support Level 56.79
3rd Support Level 55.87

See More

52-Week High 62.89
Last Price 58.22
Fibonacci 61.8% 55.11
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.